Recent update on anti-tumor mechanisms of valproic acid in glioblastoma multiforme

IF 2.9 4区医学 Q2 PATHOLOGY Pathology, research and practice Pub Date : 2024-10-03 DOI:10.1016/j.prp.2024.155636

Abulfazl Vatankhah , Sepehr Hoseinzadeh Moghaddam , Sadaf Afshari , Amir R. Afshari , Prashant Kesharwani , Amirhossein Sahebkar

{"title":"Recent update on anti-tumor mechanisms of valproic acid in glioblastoma multiforme","authors":"Abulfazl Vatankhah , Sepehr Hoseinzadeh Moghaddam , Sadaf Afshari , Amir R. Afshari , Prashant Kesharwani , Amirhossein Sahebkar","doi":"10.1016/j.prp.2024.155636","DOIUrl":null,"url":null,"abstract":"<div><div>Glioblastoma multiforme (GBM) is a malignant tumor of the brain that is considered to be incurable. Currently, surgical removal of tumors, chemotherapy with temozolomide, and radiation treatment remain established options for treatment. Nevertheless, the prognosis of those with GBM continues to be poor owing to the inherent characteristics of tumor growth and spread, as well as the resistance to treatment. To effectively deal with the present circumstances, it is vital to do extensive study to understand GBM thoroughly. The following piece provides a concise overview of the most recent advancements in using valproic acid, an antiseizure medication licensed by the FDA, for treating GBM. In this review, we outline the most recent developments of valproic acid in treating GBM, as well as its fundamental mechanisms and practical consequences. Our goal is to provide a greater understanding of the clinical use of valproic acid as a potential therapeutic agent for GBM.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"263 ","pages":"Article 155636"},"PeriodicalIF":2.9000,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology, research and practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0344033824005478","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Glioblastoma multiforme (GBM) is a malignant tumor of the brain that is considered to be incurable. Currently, surgical removal of tumors, chemotherapy with temozolomide, and radiation treatment remain established options for treatment. Nevertheless, the prognosis of those with GBM continues to be poor owing to the inherent characteristics of tumor growth and spread, as well as the resistance to treatment. To effectively deal with the present circumstances, it is vital to do extensive study to understand GBM thoroughly. The following piece provides a concise overview of the most recent advancements in using valproic acid, an antiseizure medication licensed by the FDA, for treating GBM. In this review, we outline the most recent developments of valproic acid in treating GBM, as well as its fundamental mechanisms and practical consequences. Our goal is to provide a greater understanding of the clinical use of valproic acid as a potential therapeutic agent for GBM.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

丙戊酸在多形性胶质母细胞瘤中抗肿瘤机制的最新进展

多形性胶质母细胞瘤（GBM）是一种被认为无法治愈的脑部恶性肿瘤。目前，手术切除肿瘤、替莫唑胺化疗和放射治疗仍是治疗的既定方案。然而，由于肿瘤生长和扩散的固有特性，以及对治疗的耐药性，GBM 患者的预后仍然不佳。要有效应对目前的情况，就必须进行广泛的研究，深入了解 GBM。下面的文章简要概述了使用丙戊酸（一种经 FDA 许可的抗癫痫药物）治疗 GBM 的最新进展。在这篇综述中，我们概述了丙戊酸治疗 GBM 的最新进展及其基本机制和实际后果。我们的目标是让大家更深入地了解丙戊酸作为一种潜在的 GBM 治疗药物在临床上的应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pathology, research and practice 医学-病理学

CiteScore

5.00

自引率

3.60%

发文量

405

审稿时长

24 days

期刊介绍： Pathology, Research and Practice provides accessible coverage of the most recent developments across the entire field of pathology: Reviews focus on recent progress in pathology, while Comments look at interesting current problems and at hypotheses for future developments in pathology. Original Papers present novel findings on all aspects of general, anatomic and molecular pathology. Rapid Communications inform readers on preliminary findings that may be relevant for further studies and need to be communicated quickly. Teaching Cases look at new aspects or special diagnostic problems of diseases and at case reports relevant for the pathologist''s practice.